Recurrent SARS-CoV-2 Omicron broadly neutralizing humanized antibodies in different single human V <sub>H</sub> 1-2-rearranging mouse models
Abstract
During V(D)J recombination, antibody diversity is enhanced by nontemplated junctional modifications that generate immensely diverse heavy chain (HC) and light chain (LC) complementarity-determining 3 antigen-contact regions (CDR3s). We previously developed a mouse model that generates diverse antibody repertoires by rearranging a single human V H 1-2 and Vκ1-33, associated with highly diverse CDR3s generated by V(D)J recombination with mouse Ds and/or Js. Immunization of this model with SARS-CoV-2 D614G spike elicited an antibody that potently neutralized SARS-CoV-2 variants through Omicron BA.2.754. Here, we report a related mouse model in which a single V H 1-2 rearranges to human D3-3 and J H 6, generating diverse HC-CDR3s much longer on average than those of our prior model. Omicron BA.4/.5 spike-ferritin nanoparticle-immunization of the new model elicited four highly related humanized antibodies that potently neutralize downstream Omicron subvariants. All four antibodies had 12 AA HC-CDR3s with two aromatic amino acids that engage an epitope comprising a hydrophobic patch opened-up by early Omicron lineage mutations and conserved in subsequent variants. Immunization of our prior, shorter CDR3-based model, elicited slightly less potent neutralizing antibodies that bound the same Omicron epitope, and were similar in all other aspects to those from the long, fully human CDR3 model. One tested antibody from each set reduced lung viral titers in a mouse-adapted BQ1.1 challenge. The antibodies we describe are related in their epitope recognition to recently described antibodies from Omicron-infected humans. These studies validate the utility of single human V H - and Vκ-rearranging mice for discovering humanized antibodies that neutralize emerging pathogens.
Article Details
Journal Info
Proceedings of the National Academy of Sciences
National Academy of Sciences
Authors (28)
Himanshu Batra
Sai Luo
Howard Hughes Medical Institute, Boston Children’s Hospital
Kevin O. Saunders
Jaclyn S. Higgins
Departments of Epidemiology and Microbiology and Immunology, University of North Carolina at Chapel Hill
Fanchong Jian
Biomedical Pioneering Innovation Center, Peking University
Jun Zhang
Md Golam Kibria
Division of Molecular Medicine, Boston Children’s Hospital, Harvard Medical School
G. M. Jonaid
Division of Molecular Medicine, Boston Children’s Hospital, Harvard Medical School
Qingchen J. Zhou
Howard Hughes Medical Institute, Boston Children’s Hospital
Amanda Eaton
Duke Human Vaccine Institute, Duke University School of Medicine
Kenneth Cronin
Duke Human Vaccine Institute, Duke University School of Medicine
Michael L. Mallory
Departments of Epidemiology and Microbiology and Immunology, University of North Carolina at Chapel Hill
Melissa Mattocks
Robert J. Edwards
Robert Parks
Duke Human Vaccine Institute, Duke University School of Medicine
Esther M. Lee
Duke Human Vaccine Institute, Duke University School of Medicine
Adam Yongxin Ye
Aimee Chapdelaine Williams
Howard Hughes Medical Institute, Boston Children’s Hospital
Geeyoun Jung
Howard Hughes Medical Institute, Boston Children’s Hospital
Katayoun Mansouri
Duke Human Vaccine Institute, Duke University School of Medicine
S. Munir Alam
Duke Human Vaccine Institute, Duke University School of Medicine
David C. Montefiori
Duke Human Vaccine Institute, Duke University Medical Center
Ming Tian
State Key Laboratory of Organic–Inorganic Composites, College of Materials Science and Engineering
Ralph S. Baric
Yunlong Cao
Biomedical Pioneering Innovation Center, Peking University
Barton F. Haynes
Bing Chen
Frederick W. Alt